Safety, Pharmacokinetics and Efficacy of KBSA301 in Severe Pneumonia (S. Aureus)

Inclusion Criteria: * Adult male or female patients ≥ 18 years and ≤ 70 years of age * Severe pneumonia caused by S. aureus (either methicillin-resistant or methicillin-sensitive) managed in an ICU * APACHE II of ≤30 at the time of diagnosis * Identification of S. aureus * Written informed consent provided by the patient, the relatives or the designated trusted person and/or according to local guidelines Exclusion Criteria: * Women of child bearing potential are excluded from the participation from the study unless they have a negative pregnancy test at baseline and during the course of the study. Postmenopausal women or females that have been surgically sterilized are allowed to participate. * Hypersensitivity to excipients or to any prescribed medication * Severe neutropenia, lymphoma or anticipated chemotherapy * Patients who have long-term tracheostomy * Current or recent investigational drug (within 30 days of enrollment, or 5 half-lives of the investigational compound, whichever is longer) * Presence of meningitis, endocarditis, or osteomyelitis * Acquired immune deficiency syndrome (AIDS) with cluster of differentiation 4 (CD4) count \<200 cells/ml * Known bronchial obstruction or a history of post-obstructive pneumonia. * Active primary lung cancer or another malignancy metastatic to the lungs * Cystic fibrosis, known or suspected Pneumocystis jiroveci pneumonia, or known or suspected active tuberculosis * Immunosuppressive therapy * Liver function deficiency * Moribund clinical condition